- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 05.12.25 | NRG Therapeutics appoints Paul Thompson as Chief Development Officer | ||
| 04.12.25 | Roche receives FDA clearance for whooping cough test | ||
| 04.12.25 | TRIMTECH Therapeutics appoints Alison Lawton as Chair of the Board | ||
| 04.12.25 | Why bad habits are sabotaging your strategic decisions | ||
| 03.12.25 | Richard Pazdur, FDA's drug evaluation chief, to leave FDA just weeks into new role | ||
| 03.12.25 | Circle Pharma appoints Anne Borgman as Chief Medical Officer | ||
| 02.12.25 | UK and US agree on landmark pharma pricing tariff deal | ||
| 02.12.25 | Danish diabetes-tech company Hedia appoints Rasmus Kofoed as CEO | ||
| 01.12.25 | Eisai submits new drug application for subcutaneous Leqembi in Japan | ||
| 01.12.25 | AstraZeneca's Imfinzi receives FDA approval for gastric and gastro-oesophageal cancers | ||
| 28.11.25 | Novartis' Itvisma gets FDA approval for spinal muscular atrophy treatment | ||
| 28.11.25 | Regeneron's Libtayo receives EC approval for skin cancer | ||
| 28.11.25 | ESMO 2025 - ensuring innovation isn't lost in translation | ||
| 27.11.25 | Sandoz launches first and only multiple sclerosis biosimilar in US | ||
| 27.11.25 | Tonix launches new oral fibromyalgia treatment | ||
| 27.11.25 | Agility in medical affairs: responding to rapid market and regulatory shifts | ||
| 27.11.25 | Optimised therapy to improve outcomes for heart attack and stroke patients | ||
| 27.11.25 | The new era of medical affairs: busting myths and supercharging strategic value | ||
| 26.11.25 | J&J's Tremfya improves symptoms of psoriatic arthritis including joint damage | ||
| 26.11.25 | Novartis announces plans for new US manufacturing hub | ||
| 25.11.25 | The most overlooked KPI in business? Joy | ||
| 25.11.25 | Reimagining pharma CX: three game-changing products driving human-centric innovation | ||
| 25.11.25 | When populism meets public health: trust under siege | ||
| 25.11.25 | The building of Aspire Pharma and values | ||
| 25.11.25 | Merck KGaA given FDA Fast Track designation for generalised myasthenia gravis drug |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .